(Q40547450)

21 September 2017

title

A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma (English)

1 reference

21 September 2017

main subject

phase II clinical trial

0 references

0 references

Andrea B Troxel

6

0 references

author name string

Susan M Talbot

1

1 reference

21 September 2017

Mary Louise Keohan

2

1 reference

21 September 2017

Mary Hesdorffer

3

1 reference

21 September 2017

Russell Orrico

4

1 reference

21 September 2017

Emilia Bagiella

5

1 reference

21 September 2017

Robert N Taub

7

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

21 September 2017

1 reference

21 September 2017

volume

98

1 reference

21 September 2017

issue

9

1 reference

21 September 2017

page(s)

1942-1946

1 reference

21 September 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

Alteration of DNA by 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (NSC-407347)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

From triazines and triazenes to temozolomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

Phase II trial of paclitaxel in patients with soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

Synovial sarcoma. Uniform response of metastases to high dose ifosfamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11730

7 January 2021

Identifiers

DOI

10.1002/CNCR.11730

1 reference

21 September 2017

1 reference